US 20190151478A1

(19) United States

(12) Patent Application Publication

VALTON et al.

(10) Pub. No.: US 2019/0151478 A1

(43) Pub. Date: May 23, 2019

(54) A METHOD OF ENGINEERING DRUG-SPECIFIC HYPERSENSITIVE T-CELLS FOR IMMUNOTHERAPY BY GENE INACTIVATION

(71) Applicant: **CELLECTIS**, Paris (FR)

(72) Inventors: **Julien VALTON**, NEW YORK, NY (US); **Veronique ZENNOU**, JERSEY CITY, NJ (US); **Philippe DUCHATEAU**, DRAVEIL (FR); **Laurent POIROT**, PARIS (FR)

(21) Appl. No.: **16/092,417**

(22) PCT Filed: **Apr. 13, 2017**

(86) PCT No.: **PCT/EP2017/058922**

§ 371 (c)(1),
(2) Date: **Oct. 9, 2018**

(30) **Foreign Application Priority Data**

Apr. 15, 2016 (DK) ..... PA 201670232

Publication Classification

(51) **Int. Cl.**

A61K 48/00	(2006.01)
A61P 35/00	(2006.01)
A61P 31/00	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 48/0091*** (2013.01); ***A61P 35/00*** (2018.01); ***A61P 31/00*** (2018.01); ***A61K 48/0058*** (2013.01); ***A61K 48/0008*** (2013.01); ***A61K 48/0066*** (2013.01)

(57) **ABSTRACT**

The present invention relates to therapeutic cells for immunotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering drug-specific hypersensitive T-cell, which can be depleted in vivo by the administration of said specific drug in case of occurrence of a serious adverse even. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer.

Specification includes a Sequence Listing.